Last reviewed · How we verify
Cefazolin and Metronidazole.
This is a combination of two antibiotics: cefazolin inhibits bacterial cell wall synthesis, while metronidazole disrupts anaerobic bacterial DNA.
This is a combination of two antibiotics: cefazolin inhibits bacterial cell wall synthesis, while metronidazole disrupts anaerobic bacterial DNA. Used for Surgical site infection prophylaxis, Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections.
At a glance
| Generic name | Cefazolin and Metronidazole. |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Beta-lactam antibiotic and nitroimidazole antibiotic combination |
| Target | Penicillin-binding proteins (cefazolin); anaerobic bacterial DNA (metronidazole) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefazolin is a first-generation cephalosporin that binds to penicillin-binding proteins and inhibits cross-linking of peptidoglycan in bacterial cell walls, leading to cell lysis. Metronidazole is a nitroimidazole that generates reactive intermediates in anaerobic bacteria, causing DNA strand breaks and cell death. Together, they provide broad-spectrum coverage against aerobic gram-positive cocci and anaerobic bacteria.
Approved indications
- Surgical site infection prophylaxis
- Mixed aerobic-anaerobic bacterial infections
- Intra-abdominal infections
Common side effects
- Diarrhea
- Nausea
- Hypersensitivity reactions (cefazolin)
- Metallic taste (metronidazole)
- Headache
Key clinical trials
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Duration of Perioperative Antibiotics in Pancreatoduodenectomy (NA)
- PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network (PHASE4)
- Are Post-operative Antibiotics Indicated in Simple Appendicitis? (NA)
- Mechanical Bowel Prep Randomized Study (NA)
- Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW) (PHASE4)
- Medical Versus Surgical Treatment for Peritonsillar Abscesses (NA)
- Antibiotic Prophylaxis in Metabolic Bariatric Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: